Acceleron Pharma, Inc. announced preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.
Advanced microscopic cameras use sophisticated sensors to capture images. New developments in sensors are bringing more features into view.
Multiplex bead-based immunoassays, such as Luminex xMAP technology, allow the simultaneous measurement of multiple analytes using a library of antibodies coupled to color-coded beads.
Symbion Systems, Inc. released the Symbion-DX, Version 2.5, which includes expanded database functionality, instrument control, spectroscopic data processing, and methods development capabilities.
Immunoassays are based on the ability of an antibody to bind with high specificity to a specific antigen molecule, producing a measurable signal that can be used to determine quantitative information of the antigen concentration.
Multiplex technology has become a powerful tool for examining analytes in a variety of biological samples. The advantages of this approach include time, sample, and cost savings relative to singleplex analysis of samples.
Researchers at The Scripps Research Institute found a temperature-sensing protein that allows calcium to pour in and activate an immune response when tripped.
At a time of unprecedented change within the pharmaceutical industry, improved insight into the process and the efficient progression of preclinical discoveries into clinical development projects is critical.
New research revealed how infection by a parasitic fungus dramatically changes the behavior of tropical of carpenter ants, causing them to become zombie-like and to die...
The barriers between the biomarker lab and the clinic are manifold, but validation and qualification are clearly the biggest. New guidelines, tools, and techniques are helping scientists mine a mountain of potential biomarkers for a few precious gems.
Impax Laboratories Inc. received a second patent lawsuit from Johnson & Johnson's Alza Corp. division related to Impax's proposed generic version of drug Concerta, which treats the attention deficit hyperactivity disorder.
Alkermes, Inc and Elan Corporation announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies (EDT), in a cash and stock transaction currently valued at approximately $960 million.
French drugmaker Sanofi-Aventis SA shortened its name to Sanofi, a move approved by shareholders at the company's annual meeting in Paris.
Over the last decade, cardiac safety concerns have become the leading reason that drugs are pulled from the market. As a result, thorough QT studies are more important than ever.